MS Speaks

Multiple Sclerosis => TREATMENTS => TYSABRI (natalizumab) => Topic started by: agate on June 25, 2026, 09:01:30 pm

Title: (Abst.) Predicting clinical progression in RRMS patients retrospectively using a myelin content proxy
Post by: agate on June 25, 2026, 09:01:30 pm

From PubMed (June 25, 2026)--"Predicting clinical progression in patients with relapsing remitting multiple sclerosis retrospectively using a myelin content proxy":


https://pubmed.ncbi.nlm.nih.gov/42341567/


This small study involved patients taking natalizumab.


According to AI, "A myelin content proxy is an indirect measurement used in neuroimaging to estimate the amount of myelin—the protective, fatty sheath insulating nerve fibers. Because directly measuring myelin requires time-consuming, specialized equipment, researchers rely on these "proxies" using standard, readily available brain scans."